This dataset contains Cancer Incidence data for Breast Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are for females segmented by age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

• The global industry was valued at US$ 1.3 Bn in 2023
• It is expected to grow at a CAGR of 16.8% from 2024 to 2034 and reach US$ 7.7 Bn by the end of 2034

Market Introduction

Attribute	Detail
Market Drivers	Rise in Incidence of Cancer with Speedy Adoption of AI by Developing Economies AI Progression

Regional Analysis of AI Adoption and Implementation in Oncology Practices

Attribute	Detail
Leading Region	North America

Global AI in Oncology Market Snapshot

Attribute	Detail
Market Size in 2023	US$ 1.3 Bn
Market Forecast (Value) in 2034	US$ 7.7 Bn
Growth Rate (CAGR)	16.8%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2023) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Cancer Type Lung Cancer Breast Cancer Colorectal Cancer Ovarian Cancer Others Application Diagnosis Treatment Selection Drug Discovery Patient Management and Care End-user Hospitals & Clinics Cancer Hospitals Research Institutes
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC
Companies Profiled	Paige.AI Tempus Ibex Medical Analytics PathAI Proscia Inc. DeepMind SOPHiA GENETICS Enlitic Prognos Health Inspirata, Inc.
Customization Scope	Available Upon Request
Pricing	Available Upon Request

BackgroundSouth Asians are a rapidly growing population in the United States. Breast cancer is a major concern among South Asian American women, who are an understudied population. We established the South Asian Breast Cancer (SABCa) study in New Jersey during early 2020 to gain insights into their breast cancer-related health attitudes. Shortly after we started planning for the study, the COVID-19 disease spread throughout the world. In this paper, we describe our experiences and lessons learned from recruiting study participants by partnering with New Jersey’s community organizations during the COVID-19 pandemic.MethodsWe used a cross-sectional design. We contacted 12 community organizations and 7 (58%) disseminated our study information. However, these organizations became considerably busy with pandemic-related needs. Therefore, we had to pivot to alternative recruitment strategies through community radio, Rutgers Cancer Institute of New Jersey’s Community Outreach and Engagement Program, and Rutgers Cooperative Extension’s community health programs. We recruited participants through these alternative strategies, obtained written informed consent, and collected demographic information using a structured survey.ResultsTwenty five women expressed interest in the study, of which 22 (88%) participated. Nine (41%) participants learned about the study through the radio, 5 (23%) through these participants, 1 (4.5%) through a non-radio community organization, and 7 (32%) through community health programs. Two (9%) participants heard about the study from their spouse. All participants were born outside the US, their average age was 52.4 years (range: 39–72 years), and they have lived in the US for an average of 26 years (range: 5–51 years).ConclusionPivoting to alternative strategies were crucial for successful recruitment. Findings suggest the significant potential of broadcast media for community-based recruitment. Family dynamics and the community’s trust in our partners also encouraged participation. Such strategies must be considered when working with understudied populations.

##

The current study aims to build the first digitalized mammogram dataset for breast cancer in Saudi Arabia, depend on the BI-RADS categories, to solve the availability problem of local public datasets by collecting, categorizing, and annotating mammogram images, supporting the medical field by providing physicians with different diagnosed cases especially in Saudi Arabia The dataset was collected from Sheikh Mohammed Hussein Al-Amoudi Center of Excellence in Breast Cancer at King Abdulaziz University in Jeddah, Saudi Arabia, from April 2019 to March 2020 and the annotated was between April and June 2020. The dataset contains 1416 cases; all cases include images with two types of views (CC and MLO) for both breasts (right and left), making a total of 5662 mammogram images. The dataset was classified into 1 to 5 categories in accordance with BI-RADS .

The first dataset available here (https://www.kaggle.com/asmaasaad/mammogram-dataset-kaumds)

the authors : Asmaa S. Alsolami, Dr.Wafaa Shalash , Dr.Wafaa Alsaggaf ,Dr. Sawsan Ashoor, Haneen Refaat and Dr.Mohammed Elmogy Our paper : https://www.mdpi.com/2306-5729/6/11/111

Acknowledgements

We would like to thank Miss Haneen Refaat and Dr. Sawsan for support us. We also would like to thank Sheikh Mohammed Hussien Al-Amoudi Center of Excellence in Breast Cancer at King Abdul-Aziz University and the Faculty of Computer and Information Technology.

The global Cancer Immunotherapy Market was valued at USD 128.74 Billion in 2023 and is projected to reach USD 238.38 Billion by 2030, registering a CAGR of 9.2% for the forecast period 2024-2030. The key driving factors for the Cancer Immunotherapy Market

The surging worldwide incidence of cancer, coupled with significant investments in the research and development of groundbreaking oncology therapies eventually drives the cancer immunotherapy market growth.

The global population continues to grow, and as people age, the risk of developing cancer increases. With more people living longer, there is a higher prevalence of cancer diagnoses. Modern lifestyles characterized by poor dietary habits, lack of physical activity, and increased exposure to environmental carcinogens have contributed to the rising incidence of cancer. Advances in medical imaging and diagnostic technologies have led to earlier and more accurate cancer detection, leading to an increase in reported cases. The use of tobacco and alcohol, known carcinogens, remains a significant contributor to cancer incidence, particularly in lung, liver, and oral cancers.

For instance, the Parker Institute for Cancer Immunotherapy has forged partnerships with researchers and industry experts to pioneer revolutionary immune-based cancer therapies. According to data from the Global Cancer Observatory, the United States recorded approximately 2,281,658 cancer diagnoses and 612,390 cancer-related fatalities in 2020. The prevalent malignancies impacting the U.S. populace encompass breast, prostate, lung, and colorectal cancers.
For instance, data from the Cancer Council reveals that Australia documented 150,000 new cancer diagnoses and 50,000 cancer-related fatalities in 2020. Consequently, the notable increase in the incidence of cancer cases is expected to propel market growth in the foreseeable future.
For instance, the Cancer Research Institute has provided funding for over 120 clinical trials and has allocated approximately USD 474 million towards research endeavors. Additionally, the Society for Immunotherapy of Cancer (SITC) is actively committed to enhancing patient outcomes by advancing the field of oncology immunotherapy. These organizations collaborate closely with scientists and researchers to explore innovative immune therapy treatment approaches.
For instance, In June 2022, a team of researchers at Stanford University secured a grant of USD 13 million from Cancer Grand Challenges, an initiative jointly supported by Cancer Research UK and the U.S. National Cancer Institute. This financial support has been granted to advance the development of cutting-edge immunotherapies, explore extrachromosomal DNA, and delve into the study of early-stage cancer

Expanding indications & personalized medicines significantly boost the cancer immunotherapy market growth.

Immunotherapies are being explored for a wide range of cancer types, including melanoma, lung cancer, bladder cancer, breast cancer, and more. As research uncovers new targets and mechanisms, the potential applications of immunotherapy continue to expand. Advances in understanding the genetic and molecular characteristics of tumors have led to the development of personalized immunotherapies. Tailoring treatments to an individual's unique tumor profile can improve response rates and reduce side effects. Thus, expanding indications & personalized medicines eventually boost the cancer immunotherapy market growth.

The Restraining Factor of Cancer Immunotherapy Market

Autoimmune reactions & skin reactions may restrain the cancer immunotherapy market growth.

Immunotherapies can trigger autoimmune reactions where the immune system mistakenly targets and damages normal cells or tissues, leading to conditions such as colitis, hepatitis, thyroiditis, and pneumonitis. Rashes, itching, and more severe skin conditions like dermatitis and bullous pemphigoid can occur as a result of immunotherapy. These several factors may hamper the cancer immunotherapy market growth.

Impact of the COVID-19 Pandemic on the Cancer Immunotherapy Market

Clinical trials are essential for testing the safety and efficacy of new cancer immunotherapies. The pandemic disrupted many clinical trials, leading to delays in drug development and regulatory approvals. These delays have affected the introduction of new treatments to the market. Shifts in Healthcare Resources: Hea...

BackgroundSouth Asians are a rapidly growing population in the United States. Breast cancer is a major concern among South Asian American women, who are an understudied population. We established the South Asian Breast Cancer (SABCa) study in New Jersey during early 2020 to gain insights into their breast cancer-related health attitudes. Shortly after we started planning for the study, the COVID-19 disease spread throughout the world. In this paper, we describe our experiences and lessons learned from recruiting study participants by partnering with New Jersey’s community organizations during the COVID-19 pandemic.MethodsWe used a cross-sectional design. We contacted 12 community organizations and 7 (58%) disseminated our study information. However, these organizations became considerably busy with pandemic-related needs. Therefore, we had to pivot to alternative recruitment strategies through community radio, Rutgers Cancer Institute of New Jersey’s Community Outreach and Engagement Program, and Rutgers Cooperative Extension’s community health programs. We recruited participants through these alternative strategies, obtained written informed consent, and collected demographic information using a structured survey.ResultsTwenty five women expressed interest in the study, of which 22 (88%) participated. Nine (41%) participants learned about the study through the radio, 5 (23%) through these participants, 1 (4.5%) through a non-radio community organization, and 7 (32%) through community health programs. Two (9%) participants heard about the study from their spouse. All participants were born outside the US, their average age was 52.4 years (range: 39–72 years), and they have lived in the US for an average of 26 years (range: 5–51 years).ConclusionPivoting to alternative strategies were crucial for successful recruitment. Findings suggest the significant potential of broadcast media for community-based recruitment. Family dynamics and the community’s trust in our partners also encouraged participation. Such strategies must be considered when working with understudied populations.

According to Cognitive Market Research, The Prostate Cancer Therapeutics Market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Prostate Cancer Therapeutics Market held the highest market revenue share in 2024.

Market Dynamics of The Prostate Cancer Therapeutics Market

Key Drivers for The Prostate Cancer Therapeutics Market

Growing Prevalence of Prostate Cancer fuels the Growth of the Prostate Cancer Therapeutics Market

The market for Prostate Cancer therapeutics is anticipated to develop in the future due to the Growing incidence of prostate cancer. According to the National Cancer Institute, the National Institute of Health (The U.S.) depicts that out of roughly 200,000 cases that were reported in 2020, there were 34,000 deaths from prostate cancer, representing a mortality rate of 5.5%. The analysis suggests that 12.1% of men are expected to develop prostate cancer in their lifetime. Thus, the mortality rate increased due to the growing prevalence of prostate cancer. For instance, in January 2024, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, it was estimated that there were about 299,010 new cases of prostate cancer and about 35,250 deaths from prostate cancer. About 1 man in 8 will be diagnosed with prostate cancer during his lifetime. Therefore, the rising incidence of cancer is driving the growth of the prostate cancer drugs market. Source:(https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html) Therefore, the rising prevalence of prostate cancer is propelling the growth of the prostate cancer therapeutics market, highlighting the urgent need for effective treatment options.

Biotechnological innovation in prostate cancer treatment drugs to Drive the Global Market of Prostate Cancer Therapeutics.

The market for prostate cancer medications is significantly influenced by the Biotechnological research and development innovation in prostate cancer treatment drugs. Recent developments in prostate cancer therapies have integrated several bioinformatics and computational biology applications to attain the best possible cancer treatment. Market participants have discovered a successful way to develop new cures and treatments with a targeted approach that includes whole-genome sequencing, exome profiling, and proteome profiling. For instance, Biopep Solutions Inc. is a privately owned development-stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. This Canada-based company focuses its efforts on the development of BPS-001, which is a complex, multivalent biologic drug that possesses anti-tumour attributes. There is a huge demand for innovation in the prostate cancer therapeutics market for products that have enhanced survival time, less toxicity, increased progression-free survival, increased efficacy, and lower cost. Source:(https://www.biopeps.com/bps-001-mechanism-of-action/) Therefore, with a growing population of elderly men worldwide, the demand for prostate cancer therapeutics is expected to soar, emphasizing the importance of tailored medical solutions to address this demographic trend.

Restraint Factor for The Prostate Cancer Therapeutics Market

Recurrent/Non-Responsive Prostate Cancer restrains the growth of the Prostate Cancer Therapeutics market.

The challenge of Recurrent/non-re...

The dataset concerns patients with lymphadenopathy (i.e., swelling of lymph nodes) due to illness or disease, such as cancer or infections. Lymph node disease involvement is due to the body’s immune response.

The cohort is a cross-institutional dataset of chest CT scans acquired from 513 patients during treatment for various cancer types, curated for the LNQ2023 MICCAI Challenge to help develop new segmentation tools from weakly annotated cases. The dataset originates from the Tumor Imaging Metrics Core (TIMC), a multi-institutional imaging core lab (Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women’s Hospital, Boston, MA, USA) that provides multimodality imaging measurements to evaluate treatment response in patients enrolled in oncology clinical trials. TIMC has processed data from over fourteen hundred clinical trials conducted in the period 2007- 2020.

The dataset comprises patients with various types of cancer. The top six primary patient cancers which accounted for 60% of all patients were: breast cancer, chronic lymphocytic leukemia (CLL), lung non-small cell cancer, Hodgkin‘s lymphoma, small cell lung cancer, and renal cell cancer. The remaining patient cancer types accounted for 40% of all patients including thyroid cancer, adenocarcinoma, endometrial adenocarcinoma, melanoma, head and neck cancer, non-Hodgkin’s lymphoma, prostate cancer, mesothelioma, esophageal cancer, ovarian cancer, and colon cancer.

All of the scans in the dataset were captured at baseline timepoints during clinical trials. The patients have likely been through standard of care before being placed on the trials, and may have even been through more than one trial. The patient's sex and primary cancer type are also provided. These patients were being treated in clinical trials for their conditions and have therefore undergone pathology review and other eligibility checks prior to enrollment. All annotators were trained radiologists or radiology domain experts with over ten years of experience. The initial localization for the lymph nodes in our partially annotated cases was performed as part of the clinical trial reads by the staff at the Tumor Imaging Metrics Core (TIMC), and each case was read by US-board certified radiologists in addition to TIMC Image Analysts. Annotators on our project extended the initial localizations into full segmentations in a subset of cases.

Volumetric measurements were performed using 3D Slicer (Pieper et al., 2004; Fedorov et al., 2012). For each patient, the CT scan as well as the bidimensional measurements of the target lymph node were loaded into 3D Slicer (version 4.11), and then the Segment Editor module was used to perform manual delineation of the lymph node boundary. The Draw tool within the Editor module was used to draw free hand boundaries on axial cross-sections while viewing the sagittal and coronal planes for reference. Excluded from the lesion boundary were large vessels, artifacts, and non-nodal components.

Snapshot img

Doxorubicin Market Size 2024-2028

The doxorubicin market size is valued to increase USD 497.4 million, at a CAGR of 6.09% from 2023 to 2028. Growing prevalence of cancer cases will drive the doxorubicin market.

Major Market Trends & Insights

North America dominated the market and accounted for a 48% growth during the forecast period.
By Formulation - Lyophilized powder segment was valued at USD 730.50 million in 2022
By Distribution Channel - Hospital pharmacy segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 72.36 million
Market Future Opportunities: USD 497.40 million
CAGR from 2023 to 2028 : 6.09%

Market Summary

The market represents a significant segment in the global cancer therapeutics industry, driven by the growing prevalence of cancer cases and the introduction of precision cancer medicine. According to the World Health Organization, there were approximately 19.3 million new cancer cases and 9.9 million deaths in 2020. Doxorubicin, an anthracycline antibiotic, is a primary chemotherapeutic agent used in the treatment of various types of cancer, including breast, lung, and heart cancer. The market's evolution is influenced by several factors, including the late diagnosis and poor survival rates of patients with cancer, creating a need for more effective and targeted therapies.
Additionally, regulatory approvals and regional market dynamics contribute to the market's ongoing development. For instance, in 2020, the FDA approved Adriamycin Liposome Injection, a doxorubicin liposome injection, for the treatment of advanced or metastatic soft tissue sarcoma. This approval marked a significant milestone in the market, expanding the application scope of doxorubicin and potentially increasing market revenue.

What will be the Size of the Doxorubicin Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Doxorubicin Market Segmented ?

The doxorubicin industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Formulation

  Lyophilized powder
  Doxorubicin injection


Distribution Channel

  Hospital pharmacy
  Retail pharmacy
  Online pharmacy
  Others


Geography

  North America

    US
    Canada


  Europe

    Germany
    UK


  APAC

    China


  Rest of World (ROW)

By Formulation Insights

The lyophilized powder segment is estimated to witness significant growth during the forecast period.

Request Free Sample

The Lyophilized powder segment was valued at USD 730.50 million in 2018 and showed a gradual increase during the forecast period.

Request Free Sample

Regional Analysis

North America is estimated to contribute 48% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How Doxorubicin Market Demand is Rising in North America Request Free Sample

The market is experiencing significant growth, with North America holding the largest share in 2023. This region's dominance can be attributed to the increasing prevalence of cancer, particularly breast cancer, which is the second leading cause of cancer deaths among women in the US. According to the Centers for Disease Control and Prevention (CDC), approximately 13% of US women will develop invasive breast cancer throughout their lifetime.

This statistic underscores the substantial demand for doxorubicin, a key anticancer drug used in the treatment of various types of cancer, including breast cancer. The market's expansion is driven by the rising incidence of cancer and the drug's efficacy in cancer treatment.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

In The market, a significant focus lies in devising effective cardiotoxicity management strategies to mitigate the mechanisms of doxorubicin-induced cardiotoxicity. The therapeutic index of doxorubicin is a critical concern, driving the exploration of novel drug delivery approaches. Assessing doxorubicin treatment response and overcoming resistance mechanisms are essential aspects of clinical trials, which account for a substantial portion of research efforts. Pharmacokinetics and pharmacodynamics play a pivotal role in understanding doxorubicin's behavior within the body. Patient selection criteria for doxorubicin therapy are meticulously evaluated to minimize toxicities. Monitoring doxorubicin-related toxicities and implementing clini

The size of the Brachytherapy Market was valued at USD 0.49 billion in 2023 and is projected to reach USD 0.77 billion by 2032, with an expected CAGR of 6.65% during the forecast period. Recent developments include: October 2021:For the treatment of aggressive prostate cancer, the Edinburgh Cancer Center announced in a published statement that it would be providing a high dose rate of brachytherapy. One of the first cancer treatment facilities in Scotland to provide HDR-BT for prostate cancer treatment. As a result, initiatives like these are anticipated to affect the market's development under investigation positively., November 2022:The Chhattisgarh state's All India Institute of Medical Sciences (AIIMS) has offered Brachytherapy to cancer patients, including those with breast cancer. As a result of the factors above, the breast cancer segment is anticipated to account for a sizeable portion of the market of brachytherapy over the forecast period., September 2020:According to the American Cancer Society, invasive breast cancer affects 1 in 8 American women (roughly 13%). According to the same source, 287,850 new cases of invasive breast cancer are anticipated to be diagnosed in women in the United States in 2022, along with 51,400 new cases of non-invasive (in situ) breast cancer.. Notable trends are: Growth in cancer prevalence to boost the market growth.

PurposeThis study aimed to develop a novel predicting model based on deep learning (DL) to predict sentinel lymph node (SLN) metastasis in breast cancer (BC) patients using ultrasound (US) imaging.MethodsA retrospective cohort consisting of 692 female BC patients from two hospitals was analyzed, with data collected from January 2020 to October 2023. Patients from Hospital A were randomly allocated to training (n = 405) and internal validation (n = 174) sets (7:3 ratio), with Hospital B patients (n = 113) serving as the external test set. A post-fusion model integrating the DeepLabV3, U-Net, and U-Net++ segmentation algorithms, respectively, was utilized to automatically delineate regions of interest (ROIs). Furthermore, three convolutional neural networks (CNNs)—ResNet50, ResNet101, and DenseNet121, respectively—were employed to analyze the cropped regions and concurrently construct a predictive model. A composite model that incorporates the DL signature (DL Sig) alongside clinical factors was developed by utilizing logistic regression (LR). A database to compare human and machine performance was created to evaluate the model’s effectiveness. A nomogram was ultimately constructed to forecast the occurrence of SLN metastasis. The evaluation of model performance involved the utilization of receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA), respectively.ResultsThe post-fusion model demonstrated a robust correlation with manual delineation, yielding Dice coefficients of 0.893 and 0.855 in the internal validation and external test sets, respectively. The ResNet50 model, recognized as the most effective base model, demonstrated an area under the curve (AUC) of 0.773 (95% CI: 0.706–0.840) and an accuracy of 68% in the internal validation set (VS). In the external test set (TS), it achieved 0.765 AUC (95% CI: 0.674–0.856) with accuracy of 74%. The integrated model, which combined the DL Sig with clinical factors, exhibited the most effective performance in forecasting SLN metastasis, achieving 0.763 AUC (95% CI: 0.671–0.855) with accuracy of 69% in the TS. The DCA demonstrated notable clinical utility in the integrated model, surpassing the performance of both senior and junior radiologists.ConclusionOur novel predictive model exhibited superior performance compared to both senior and junior radiologists in predicting SLN metastasis. Its capability for automatic segmentation and prediction highlights its potential for clinical applications.